54-92-2 Usage
Uses
Used in Pharmaceutical Industry:
Iproniazid is used as an antidepressant for treating depressive disorders. Its action as an irreversible and nonselective monoamine oxidase inhibitor helps in regulating mood and alleviating symptoms of depression.
Used in Research and Development:
In addition to its clinical applications, iproniazid is also utilized in research and development for studying the mechanisms of depression and the effects of monoamine oxidase inhibitors on the central nervous system. This helps in the development of new and improved antidepressant medications.
Used in Combination Therapies:
Iproniazid may be used in combination with other medications to enhance the overall treatment efficacy for patients with severe or treatment-resistant depression. The synergistic effects of combining iproniazid with other antidepressants can lead to better outcomes for patients.
Used in Historical Context:
Iproniazid has a historical significance in the development of modern antidepressant medications. Its discovery and use have paved the way for the development of other monoamine oxidase inhibitors and contributed to a better understanding of the role of monoamines in mood regulation.
Originator
Marsilid,Roche,US,1952
Manufacturing Process
A mixture of 40 g of isonicotinyl hydrazine and 600 cc of acetone was heated
on a steam bath until solution was complete. Upon cooling the reaction
mixture, 1-isonicotinyl-2-isopropylidene hydrazine precipitated in the form of
white needles; MP 161°C to 161.5°C.A solution of 20 g of 1-isonicotinyl-2-isopropylidene hydrazine in 150 cc of
methanol was reduced with hydrogen at room temperature and 50 psi using
300 mg of platinum black as a catalyst.
Therapeutic Function
Antidepressant, Monoamine oxidase inhibitor
World Health Organization (WHO)
Iproniazid, a monoamine oxidase inhibitor (MAOI), was
introduced in 1952 for the treatment of depressive illness. Subsequently concern
regarding potentially serious interactions between MAOIs and foods containing
tyramine inspired much restrictive regulatory action. However, MAOIs still retain a
place in the treatment of serious depressive illness although there is no
international consensus on which compounds should be preferred. Thus iproniazid
remains available in several countries.
Purification Methods
Crystallise it from *benzene or *benzene /pet ether and dry it in a vacuum. It is soluble in H2O and EtOH. [Fox & Gibas J Org Chem 18 994 1953.] The dihydrochloride has m 227-228o (from EtOH). [Beilstein 22 III/IV 551.] It is an antidepressant.
Check Digit Verification of cas no
The CAS Registry Mumber 54-92-2 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 4 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 54-92:
(4*5)+(3*4)+(2*9)+(1*2)=52
52 % 10 = 2
So 54-92-2 is a valid CAS Registry Number.
InChI:InChI=1S/C9H13N3O/c1-7(2)11-12-9(13)8-3-5-10-6-4-8/h3-7,11H,1-2H3,(H,12,13)
54-92-2Relevant academic research and scientific papers
Discovery of a novel series of indolyl hydrazide derivatives as diacylglycerol acyltransferase-1 inhibitors
Kim, Minkyoung,Kwon, Jinsun,Kim, Mun Ock,Singh, Sarbjit,Kim, Sang Kyum,Lee, Kyeong,Lee, Kiho,Lee, Hyun Sun,Choi, Yongseok
supporting information, p. 628 - 635 (2015/05/04)
A novel series of hydrazide derivatives were synthesized as potential diacylglycerol acyltransferase (DGAT) inhibitors. Among them, compounds 8u and 8v exhibited selective and potent DGAT-1 inhibitory activities. In addition, compound 8u dose-dependently inhibited triglyceride synthesis in HepG2 cell lines. Furthermore, treatment with compound 8u for an oral lipid tolerance test showed a significant decrease in plasma triglyceride levels compared with vehicle-treated control animals, indicating delayed absorption of triglyceride after an acute lipid challenge.
Synthesis and in vitro antimicrobial and antitumoral screening of novel lipophilic isoniazid analogues. VI
Vigorita,Ottana,Maccari,Monforte,Bisignano,Pizzimenti
, p. 267 - 276 (2007/10/03)
Various kinds of lipophilic analogues of isonicotinic acid hydrazide (Isoniazid) were synthesized and in vitro explored in a search for antimycobacterial agents with extended activity spectrum against pathogens responsible for the AIDS-associated diseases. The primary in vitro screening showed that a) isonicotinoylhydrazones 1a, 1b, 1d, 1e are more active than the parent drug against non-tubercular mycobacteria (MIC ranging between 0.5 and 4 μg/ml), b) isonicotinohydrazides 6b and 6e display interesting antibacterial activity on some Gram + and Gram - strains, and c) trifluoromethyl-containing compounds 1a and 2c inhibit the growth of several human tumor cell lines at doses between 10-5 and 10-6 M. On the contrary, none of the tested analogues significantly counteracts the cytopathogenicity induced by HIV and HSV viruses.
